Mammary Cell News Volume 10.13 | Apr 5 2018

TOP STORY

Metabolic Enzyme PFKFB4 Activates Transcriptional Coactivator SRC-3 to Drive Breast Cancer

The authors showed that the metabolic enzyme 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 4 (PFKFB4) regulates transcriptional reprogramming by activating the oncogenic steroid receptor coactivator-3 (SRC-3). [Nature] Abstract | Press Release

(Ranked by impact factor of the journal)

Increased Autophagy Blocks HER2-Mediated Breast Tumorigenesis

Scientists explored the regulation of autophagy in breast cancer cells by human epidermal growth factor receptor 2 (HER2) in vitro and the effects of genetic and pharmacological strategies to increase autophagy on HER2-driven breast cancer growth in vivo. [Proc Natl Acad Sci USA] Full Article

Loss of TDP43 Inhibits Progression of Triple-Negative Breast Cancer in Coordination with SRSF3

Researchers identified TAR DNA-binding protein 43 (TDP43) as an important splicing regulator responsible for the unique splicing profile in triple-negative breast cancer. [Proc Natl Acad Sci USA] Full Article

Identification of CDC25 as a Common Therapeutic Target for Triple-Negative Breast Cancer

Scientists performed kinome/phosphatase inhibitor screens on primary mouse Rb/p53^–, Pten/p53^–, and human RB1/PTEN/TP53^–deficient triple-negative breast cancer cell lines and identified CDC25 phosphatase as a common target. [Cell Rep] Full Article | Press Release | Graphical Abstract

Multifaceted Impact of MicroRNA 493-5p on Genome-Stabilizing Pathways Induces Platinum and PARP Inhibitor Resistance in BRCA2-Mutated Carcinomas

Researchers identified a microRNA, miR-493-5p, that induced platinum/PARP inhibitor resistance exclusively in BRCA2-mutated carcinomas. [Cell Rep] Full Article | Press Release | Graphical Abstract

The p85 Isoform of the Kinase S6K1 Functions as a Secreted Oncoprotein to Facilitate Cell Migration and Tumor Growth

The authors reported that p85^S6K1, the longest isoform of S6K (ribosomal protein S6 kinase), but not the shorter isoform p70^S6K1 or p56^S6K2, was secreted from cancer cells through its HIV TAT-like, N-terminal six-arginine motif. [Sci Signal] Abstract

Heterogeneity of Human Breast Stem and Progenitor Cells as Revealed by Transcriptional Profiling

Investigators identified single aldehyde dehydrogenase positive cells with a hybrid epithelial/mesenchymal phenotype that express genes associated with aggressive triple-negative breast cancers. [Stem Cell Reports] Full Article

The Secretome from Bovine Mammosphere-Derived Cells (MDC) Promotes Angiogenesis, Epithelial Cell Migration, and Contains Factors Associated with Defense and Immunity

Scientists showed that the secretome, or collective factors, produced by MDC promotes angiogenesis, epithelial cell migration, and contains proteins associated with immunity and defense; all of which are necessary for healing damaged mammary gland tissue. [Sci Rep] Full Article

SNAIL1 Action in Tumor Cells Influences Macrophage Polarization and Metastasis in Breast Cancer through Altered GM-CSF Secretion

Researchers showed that the action of SNAIL1 in primary breast tumor cells is required for breast tumor growth and metastasis. [Oncogenesis] Full Article

Magnetic Nanoparticle-Mediated Gene Therapy to Induce Fas Apoptosis Pathway in Breast Cancer

Magnetic nanoparticles and lipid-based gene transfection methods were performed to provide active Fas expression in breast cancer cells. [Cancer Gene Ther] Abstract

Targeting Phosphopeptide Recognition by the Human BRCA1 Tandem BRCT Domain to Interrupt BRCA1-Dependent Signaling

The authors developed Bractoppin, a drug-like inhibitor of phosphopeptide recognition by the human BRCA1 tandem BRCA1 C-terminal (BRCT) domain, which selectively inhibits substrate binding with nanomolar potency in vitro. [Cell Chem Biol] Full Article | Graphical Abstract

Cytokine-Mediated Therapeutic Resistance in Breast Cancer

The authors discuss the mechanisms by which cytokines promote therapeutic resistance of breast cancer (BCa) and suggest a potential approach for improving BCa therapeutics by inhibition of exosome function. [Cytokine] Abstract

Visit our reviews page to see a complete list of reviews in the mammary cell research field.

SELLAS Life Sciences Announces Positive Interim Data from Phase IIb NeuVax™ (Nelipepimut-S) Clinical Trial in Combination with Herceptin^® in HER2 1⁺/2⁺ Breast Cancer Patients

SELLAS Life Sciences Group Inc. announced positive interim data from the prospective, randomized, single-blinded, controlled Phase IIb independent investigator-sponsored clinical trial of trastuzumab^+/- nelipepimut-S in HER2 1⁺/2⁺ breast cancer patients in the adjuvant setting to prevent recurrences. [SELLAS Life Sciences Group Inc.] Press Release

NCCN Guidelines for Central Nervous System Cancers Include NERLYNX^® (Neratinib) in Combination with Capecitabine or Paclitaxel as Treatment Options for Patients with Breast Cancer Brain Metastases

Puma Biotechnology, Inc. announced that NERLYNX^® has been included as a recommended treatment option in the latest National Comprehensive Cancer Network (NCCN) clinical practice guidelines in oncology central nervous system cancers for breast cancer patients with brain metastases. [Puma Biotechnology, Inc.] Press Release

The European Medicines Agency Accepts Regulatory Submission for LYNPARZA^® (Olaparib) in BRCA-Mutated HER2-Negative Metastatic Breast Cancer

AstraZeneca and Merck announced that the European Medicines Agency has validated for review the Marketing Authorization Application for LYNPARZA^® for use in patients with deleterious or suspected deleterious BRCA-mutated, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer who have been previously treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. [Merck & Co., Inc.] Press Release

Unnecessary Exclusions Shut Patients out of Clinical Trials

The FDA will hold a public meeting in Washington to discuss issues related to clinical trial eligibility criteria. Researchers, study sponsors, patients, and the general public will have an opportunity to share their experiences and tell our regulators why it’s time to revisit the guidelines. [STAT] Editorial

In Emotional Speech, CDC’s New Leader Vows to Uphold Science

Robert Redfield Jr., the new director of the Centers for Disease Control and Prevention (CDC), gave a deeply personal agency-wide address in which he repeatedly underscored the importance of science and data and said the CDC’s most critical public health mission is to protect Americans “from that which we don’t expect”. [The Washington Post] Editorial

Cancer Researcher at the Ohio State University Resigns following Multiple Misconduct Findings

A cancer researcher has resigned from The Ohio State University in Columbus after the institution determined he had committed misconduct in eight papers. His work in designing anticancer compounds had led to millions of dollars in funding and multiple patents, as well as two compounds in clinical trials. [ScienceInsider] Editorial

French Universities Cancel Subscriptions to Springer Journals

French research organizations and universities have canceled their subscriptions to Springer journals, due to an impasse in fee negotiations between the publisher and Couperin.org, a national consortium representing more than 250 academic institutions in France. [The Scientist] Editorial

EU Copyright Reforms Draw Fire from Scientists

An influential committee of the European Parliament is due to vote on changes to copyright regulations in the European Union (EU), but the latest drafts of the rules have triggered a wave of criticism from open-science advocates. They say that the proposals will stifle research and scholarly communication. [Nature News] Editorial

2018 March for Science Will Be Far More than Street Protests

The March for Science has matured. It may even have outgrown its name. [ScienceInsider] Editorial

NEW 6^th Annual German Stem Cell Network (GSCN) Conference
September 19-21, 2018
Heidelberg, Germany

Visit our events page to see a complete list of events in the community.

NEW Project Manager – Breast Cancer Research (University of Cambridge)

NEW Postdoctoral Fellow – Cancer Research (Indiana Uniersity School of Medicine)

NEW Postdoctoral Fellows – Molecular and Translational Cancer Biology (Thomas Jefferson University)

NEW Tenure Track Faculty Position – Cancer Research (University of Alabama at Birmingham)

Postdoctoral Research Associate – Stem Cell Biology (King’s College London)

Postdoctoral Researcher – Breast Cancer (UT Southwestern Medical Center)

Postdoctoral Fellow – Stem Cells and Breast Cancer (Albert Einstein College of Medicine)

Postdoctoral Training Fellow – Endocrinology (Institute of Cancer Research)

Staff Position – Breast Cancer Tumor Immunology (Cleveland Clinic Taussig Cancer Institute)

Research Fellow – Breast Cancer (Dana-Farber Cancer Institute)

Postdoctoral Researcher – Cancer and RNA Biology (University of Texas)

Graduate Student – Breast and Colorectal Cancer (Dalhousie University)

Postdoctoral Fellow – Cancer Research (Memorial Sloan Kettering Cancer Center)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here.